StatLab Expands with Diapath Acquisition for European Growth

02 Sep, 2024

StatLab Expands with Diapath Acquisition for European Growth

StatLab Medical Products, a prominent US-based developer of medical diagnostic supplies, is set to acquire Diapath, an Italian company specializing in histology and cytology products. This acquisition will enable StatLab to broaden its market presence across Europe and unlock significant growth potential. The deal is a key part of StatLab's strategy to offer a comprehensive range of products for the anatomic pathology workflow.

The acquisition is scheduled to close in the third quarter of 2024. Once finalized, Diapath's founder, Vladimiro Bergamini, will transition to a senior advisor role at StatLab, while COO Alberto Battistel will join StatLab's executive leadership team. Diapath, based in Martinengo near Bergamo, Italy, provides essential equipment such as tissue processors, stainers, embedding centers, and microtomes. Beyond its strong presence in Italy, Diapath’s subsidiaries also contribute to its growth in Germany and France.

This strategic move allows StatLab to expand Diapath's equipment brand into global markets, including the US, and enhance its foothold in Europe. The acquisition marks a significant milestone in StatLab’s ongoing efforts to improve and diversify its product offerings within the global medical diagnostic industry.